Seroprevalence of Bordetella pertussis among a nationally representative sample of Iranian pediatric population The childhood and adolescence surveillance and prevention of adult noncommunicable disease V study

Pertussis is a vaccine‑preventable respiratory infection and seroepidemiology of the infection could be a marker of the pertussis immunity in a population. In many countries, despite vaccination coverage, high prevalence of pertussis has been observed. The present study aimed to evaluate the immunoglobulin G (IgG) antibody against pertussis and the role of demographic and anthropometric variables on the immunity rate in the Iranian pediatric population to evaluate the impact of existing immunization program in order to envisage future vaccination strategies to prevent infection.

In a cross‑sectional multi‑centric study, 1593 samples of the students aged 7–18 years, who had been enrolled in a national survey (Childhood and Adolescence Surveillance and Prevention of Adult Noncommunicable disease‑V), were randomly selected and tested for IgG antibody against Bordetella pertussis (BP) by enzyme‑linked immunosorbent assay. The age, gender, education, residency, geographical region, and body mass index (BMI) were extracted from the questionnaires of the COSPIAN‑Survey. Multiple logistic regression models were used to assess the associations between the variables with the IgG antibody against BP. Data were presented by odds ratio (OR), 95% confidence interval (95% CI) and P values (P): (OR [95% CI]; P).

Subjects were consisted of 774 boys and 750 girls, with a mean (standard deviation) age of 12.39 (3.03) years. Overall, BP seroprevalence was 59.8%. There were higher BMI values in seronegative ones versus seropositive (18.62 ± 4.07 vs. 18.15 ± 3.94, P = 0.041, 95% CI = 0.23 [0.02–0.92]). However, the categorized BMI for age was not significantly associated with IgG levels (0.27 [0.25–0.29]; 0.27). BP seroprevalence was not significantly different between geographical regions (0.06 [0.05–0.07]; 0.06), genders (1.17 [0.93–1.47]; 0.18), area of residence (1.07 [0.82–1.4]; 0.61), and educational levels (0.94 [0.75–1.19]; 0.62).

IgG antibody against pertussis was not detected in nearly 40% of the subjects who had history of vaccination against pertussis. It is recommended to monitor the incidence of pertussis in high‑risk populations closely and administer a booster dose of acellular pertussis vaccine in adolescents.